A 15% reduction in Lp(a) did not affect arterial wall inflammation despite a spectacular reduction in LDL, suggesting a residual risk associated with Lp(a).

“they showed that even though you you reduce ldl by uh i don't know what percentage but it was a spectacular reduction in ldl a very small reduction in lpa of 15 you don't see any effect on arterial wall inflammation so that means that you know there's an important uh residual risk that's associated with lba because if you lower ldl with pcsk9 inhibitors you know there's no outcomes data although they did link lpa with recurrent cardiovascular disease in this in these trials you see uh that the pro-inflammatory effect of lpa on the vasculature still remains”